MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM) Meeting Abstract
| Authors: | Dholaria, B.; Bahlis, N.; Raje, N.; Costello, C.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; Basu, C.; Skoura, A.; Chan, E.; Trudel, S.; Jakubowiak, A.; Chu, M.; Gasparetto, C.; Dalovisio, A.; Sebag, M.; Lesokhin, A. |
| Abstract Title: | MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM) |
| Meeting Title: | 18th International Myeloma Workshop (IMW) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-10-01 |
| Start Page: | S17 |
| Language: | English |
| ACCESSION: | WOS:000717640800027 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)02100-5 |
| Notes: | Meeting Abstract: OAB-026 -- Source: Wos |
